Skip to main content

INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML

Publication ,  Conference
Cortes, J; DeAngelo, D; Wang, E; Arana-Yi, C; Zweidler-McKay, P; Munteanu, M; Andreu-Vieyra, C; Erba, H; Blum, W; Traer, E
Published in: HAEMATOLOGICA
June 26, 2017

Duke Scholars

Published In

HAEMATOLOGICA

ISSN

0390-6078

Publication Date

June 26, 2017

Volume

102

Start / End Page

217 / 218

Location

Madrid, SPAIN

Publisher

FERRATA STORTI FOUNDATION

Conference Name

22nd Congress of the European-Hematology-Association

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cortes, J., DeAngelo, D., Wang, E., Arana-Yi, C., Zweidler-McKay, P., Munteanu, M., … Traer, E. (2017). INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML. In HAEMATOLOGICA (Vol. 102, pp. 217–218). Madrid, SPAIN: FERRATA STORTI FOUNDATION.
Cortes, J., D. DeAngelo, E. Wang, C. Arana-Yi, P. Zweidler-McKay, M. Munteanu, C. Andreu-Vieyra, H. Erba, W. Blum, and E. Traer. “INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML.” In HAEMATOLOGICA, 102:217–18. FERRATA STORTI FOUNDATION, 2017.
Cortes J, DeAngelo D, Wang E, Arana-Yi C, Zweidler-McKay P, Munteanu M, et al. INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 217–8.
Cortes J, DeAngelo D, Wang E, Arana-Yi C, Zweidler-McKay P, Munteanu M, Andreu-Vieyra C, Erba H, Blum W, Traer E. INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 217–218.

Published In

HAEMATOLOGICA

ISSN

0390-6078

Publication Date

June 26, 2017

Volume

102

Start / End Page

217 / 218

Location

Madrid, SPAIN

Publisher

FERRATA STORTI FOUNDATION

Conference Name

22nd Congress of the European-Hematology-Association

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology